Stockscreener 앱 받기
29.27
7.33%
2.00
시간 외 거래:
29.30
0.03
+0.10%
전일 마감가:
$27.27
열려 있는:
$27.68
하루 거래량:
3.12M
Relative Volume:
2.39
시가총액:
$3.73B
수익:
$8.40M
순이익/손실:
$-237.42M
주가수익비율:
-15.23
EPS:
-1.9213
순현금흐름:
$-377.03M
1주 성능:
+4.02%
1개월 성능:
+53.57%
6개월 성능:
+63.34%
1년 성능:
+784.29%
1일 변동 폭
$27.45
$29.72
1주일 범위
$25.48
$29.72
52주 변동 폭
$3.245
$30.60
Alumis Inc Stock (ALMS) Company Profile
명칭
Alumis Inc
전화
650-231-6625
주소
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALMS vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
29.27 | 3.48B | 8.40M | -237.42M | -377.03M | -1.9213 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.93 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.50 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-11 | 개시 | Raymond James | Strong Buy |
| 2026-02-25 | 개시 | Stifel | Buy |
| 2026-01-21 | 개시 | Chardan Capital Markets | Buy |
| 2025-07-25 | 개시 | Wells Fargo | Overweight |
| 2025-06-10 | 재개 | Guggenheim | Buy |
| 2025-01-30 | 개시 | Oppenheimer | Outperform |
| 2024-10-31 | 개시 | Robert W. Baird | Outperform |
| 2024-10-17 | 개시 | H.C. Wainwright | Buy |
| 2024-07-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-07-23 | 개시 | Guggenheim | Buy |
| 2024-07-23 | 개시 | Leerink Partners | Outperform |
| 2024-07-23 | 개시 | Morgan Stanley | Overweight |
모두보기
Alumis Inc 주식(ALMS)의 최신 뉴스
[144] ALUMIS INC. SEC Filing - Stock Titan
Price to sales forward of Alumis Inc. – NASDAQ:ALMS - TradingView
Form 4 Alumis Inc For: 2 July By Investing.com - Investing.com Canada
Alumis (ALMS) director Lynn Tetrault receives RSU and stock option awards - Stock Titan
Director at ALUMIS (NASDAQ: ALMS) receives RSU and option grants - Stock Titan
[Form 4] ALUMIS INC. Insider Trading Activity - Stock Titan
Alumis (ALMS) director awarded new RSUs and stock options - Stock Titan
Alumis (ALMS) director Akkaraju receives RSUs, options and reports fund stakes - Stock Titan
Form 13D/A Alumis Inc. For: 2 July By Investing.com - Investing.com Nigeria
Alumis (ALMS) major holder keeps 15.1M-share stake as ownership hits 12.3% - Stock Titan
[8-K] ALUMIS INC. Reports Material Event - Stock Titan
Stifel and Guggenheim Stay Bullish on Alumis (ALMS) - Insider Monkey
Enterprise value to EBITDA forward of Alumis Inc. – NASDAQ:ALMS - TradingView
Wells Fargo Maintains Alumis(ALMS.US) With Buy Rating, Maintains Target Price $51 - Moomoo
Enterprise value to revenue forward of Alumis Inc. – NASDAQ:ALMS - TradingView
Alumis Inc.(NasdaqGS: ALMS) added to Russell 2500 Growth Benchmark - marketscreener.com
ALMS Forecast — Price Target — Prediction for 2027 - TradingView
Alumis Inc.(NasdaqGS: ALMS) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Alumis Unveils Breakthrough TYK2 Inhibitors: Leading Clinical Results in Psoriasis and Lupus, $180B+ Market Opportunity by 2030 318 – Minichart - Minichart
Alumis Inc.(NasdaqGS: ALMS) dropped from Russell 2000 Value Benchmark - marketscreener.com
Alumis updates corporate presentation highlighting envudeucitinib Phase 3 wins, SLE and NDA timing - TradingView
Alumis (NASDAQ: ALMS) posts updated June 2026 corporate presentation - Stock Titan
Alumis Inc.(NasdaqGS: ALMS) added to Russell 2000 Growth Benchmark - marketscreener.com
Alumis (ALMS) Is Up 7.3% After Russell Reclassifies It Into Growth Indices What’s Changed - simplywall.st
Alumis Inc.(NasdaqGS: ALMS) dropped from Russell 3000E Value Benchmark - marketscreener.com
Oppenheimer Maintains Alumis(ALMS.US) With Buy Rating, Maintains Target Price $55 - Moomoo
Alumis: Is Envudeucitinib The 'Real Deal?' We Should Find Out Soon - Seeking Alpha
Alumis Inc. Actuals & Estimates (BOATS:ALMS) - TradingView
Alumis | 4: Statement of changes in beneficial ownership of securities-10% Owner Foresite Capital Management VI LLC - Moomoo
Alumis Inc. (ALMS) Sees Modest Gain as Stock Consolidates Near ResistanceETF Liquidity - dars.gov.et
Alumis Inc (ALMS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Alumis Inc (ALMS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Alumis Inc (ALMS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Alumis Inc (ALMS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Alumis Inc (ALMS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Alumis Inc (ALMS) Institutional Confidence - TradingKey
ALMS Q1 2026 Earnings: Narrower-than-Expected Loss Lifts SharesROIC Trend Report - dars.gov.et
Alumis Inc (ALMS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Alumis Inc (ALMS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Alumis Inc (ALMS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Alumis Stock Sinks As Revenue Shock Jolts Hopes - TipRanks
ALMS Q1 2026 Earnings: EPS Beat Drives 15.55% Stock SurgeRevenue Warning Signal - newsline.com
Alumis | ARS: Annual Report to Security Holders - Moomoo
Alumis (ALMS) Sees 10.3% Surge, Reaching $23.06 - GuruFocus
ALUMIS INC (ALMS) Stock Chart - ChartMill
Alumis Shares Surge 16% as Traders Eye New Drug Move - TechStock²
Why Alumis Inc. Shares Are Suddenly Climbing - TipRanks
ALMS Q1 2026 Earnings: Narrower-Than-Expected Loss Propels Stock HigherMargin Compression Risk - newsline.com
Alumis | SCHEDULE 13D/A: Others - Moomoo
ACT CAPITAL MANAGEMENT, LLC's Alumis Inc(ALMS) Holding History - GuruFocus
Why Alumis Inc. Stock Is Sinking So Sharply - TipRanks
Alumis Inc (ALMS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Alumis Inc 주식 (ALMS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Drappa Jorn | Chief Medical Officer |
May 22 '26 |
Option Exercise |
6.65 |
26,852 |
178,649 |
59,339 |
| AKKARAJU SRINIVAS | Director |
Jan 09 '26 |
Buy |
17.00 |
588,235 |
9,999,995 |
1,853,488 |
| Foresite Labs, LLC | 10% Owner |
Jan 08 '26 |
Buy |
17.00 |
411,764 |
6,999,988 |
5,702,536 |
| Foresite Capital Management VI | 10% Owner |
Jan 08 '26 |
Buy |
17.00 |
411,764 |
6,999,988 |
5,702,536 |
| Tananbaum James B. | Director |
Jan 08 '26 |
Buy |
17.00 |
411,764 |
6,999,988 |
5,702,536 |
| AKKARAJU SRINIVAS | Director |
Dec 05 '25 |
Buy |
9.84 |
186,377 |
1,833,760 |
1,265,253 |
| AKKARAJU SRINIVAS | Director |
Dec 03 '25 |
Buy |
7.75 |
100,000 |
775,000 |
1,012,849 |
| AKKARAJU SRINIVAS | Director |
Dec 02 '25 |
Buy |
7.55 |
96,000 |
724,800 |
912,849 |
| AKKARAJU SRINIVAS | Director |
Dec 04 '25 |
Buy |
8.18 |
66,027 |
540,101 |
1,078,876 |
| AKKARAJU SRINIVAS | Director |
Dec 01 '25 |
Buy |
7.46 |
86,350 |
644,171 |
816,849 |
1.18%
2.48%
자본화:
|
볼륨(24시간):